Turnstone Biologics Corp.
turnstonebio.comNo Longer Reporting
The company has not filed an annual or quarterly report since its Q2 FY2025 10-Q, filed Aug 8, 2025. Its latest SEC filing is a SCHEDULE 13G/A from Nov 14, 2025.
10-Q for Q2 FY2025, filed Aug 8, 2025
Sources
The sections below describe the company as of the FY2024 annual report.
What Did They Do?
Developed experimental cell therapies that select and expand tumor-reactive immune cells to treat solid tumors.
10-K for FY2024, filed Mar 31, 2025
Sources
How Were They Changing?
Since the FY2024 annual report
Latest quarter: Q2 FY2025, the three months to Jun 30, 2025
- Net income
-
Sources
10-Q for Q2 FY2025, filed Aug 8, 2025
−$5.5MView ↗
- ▼ −74% (Loss)
- vs −$21.3M in Q2 FY2024
-
Aug 11, 2025
XOMA completed its acquisition of Turnstone
Turnstone became XOMA’s wholly owned subsidiary; shareholders received cash plus a contingent value right for each share.
Sources
8-K, filed Aug 11, 2025
Pursuant to the Merger Agreement, and upon the terms and subject to the conditions thereof, on August 8, 2025, Purchaser completed a tender…View ↗
Loading...
Comments
